2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow telitacicept: new trials by email Literature Review of telitacicept trials Research Report on telitacicept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy IBI3034, Placebo, Telitacicept - IgA Nephropathy (IgAN) | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 100 | 2026-10-15 | 2026-10-21 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) Telitacicept 160mg, Prednisone (and methylprednisolone), Cyclophosphamide - Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1 / Phase 2 | Active not recruiting | Renmin Hospital of Wuhan University | 15 | 2024-10-10 | 2024-10-24 |
| A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus Telitacicept - Systemic Lupus Erythematosus | Phase 1 | Completed | RemeGen Co., Ltd. | 16 | 2023-05-25 | 2026-03-09 |
| Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus Telitacicept, standard therapy - Systemic Lupus Erythematosus | Phase 1 | Completed | RemeGen Co., Ltd. | 92 | 2022-05-11 | 2023-12-06 |
Lupus Erythematosus, Systemic (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Glomerulonephritis, IGA (1)
RemeGen Co., Ltd. (2) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Renmin Hospital of Wuhan University (1)
China (4)